LakeShore Biopharma CFO reports option holdings

LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares.

Accepted by SEC EDGAR 04/01/2026 - 10:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

LakeShore Biopharma Co., Ltd. director and Chief Financial Officer Yu Rui reported initial beneficial ownership of a share option covering 203,464 underlying Ordinary Shares. The option has an exercise price of $1.225 per share and expires on December 13, 2034.

According to the vesting terms, 25% of the underlying shares vest on December 31, 2024, and the remaining 75% vest in three equal annual installments on each anniversary of the December 13, 2024 grant date, subject to Yu Rui’s continued service to the company. The filing does not reflect any purchase or sale of shares, only this option holding.

Insider Trade Summary

Holdings reported, no transactions

Holdings

Insider Yu Rui

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Holding	Share Option (Right to Buy)	--	--	--

Holdings: Share Option (Right to Buy) — 203,464 contracts (Direct)

Footnotes (1)

1. F1. The option vests as to 25% of the underlying shares on December 31, 2024, and the remaining 75% vests in three equal annual installments on each anniversary of the grant date (December 13, 2024) thereafter, subject to the Reporting Person's continued service to the Issuer.

Key Figures

Underlying shares: 203,464 shares Exercise price: $1.225 per share Option expiration: December 13, 2034 +2 more

5 metrics

Underlying shares 203,464 shares Underlying Ordinary Shares for reported share option

Exercise price $1.225 per share Exercise price of share option (Right to Buy)

Option expiration December 13, 2034 Expiration date of reported share option

Initial vesting tranche 25% of shares Vests on December 31, 2024

Remaining vesting 75% of shares Vests in three equal annual installments after December 13, 2024

Key Terms

Share Option (Right to Buy), Ordinary Shares, vesting, grant date

4 terms

Share Option (Right to Buy) financial

"security_title: "Share Option (Right to Buy)""

Ordinary Shares financial

"underlying_security_title: "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

vesting financial

"The option vests as to 25% of the underlying shares on December 31, 2024"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

grant date financial

"on each anniversary of the grant date (December 13, 2024) thereafter"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider position did Yu Rui report in LakeShore Biopharma (LSB)?

Yu Rui reported holding a share option over 203,464 underlying Ordinary Shares. This Form 3 filing reflects initial beneficial ownership as a director and Chief Financial Officer, rather than a new market transaction or change in share ownership levels.

What is the exercise price of Yu Rui’s LakeShore Biopharma (LSB) option?

The reported share option has an exercise price of $1.225 per Ordinary Share. This is the price Yu Rui would pay per share upon exercise, subject to vesting conditions and the option’s stated expiration on December 13, 2034.

How many LakeShore Biopharma (LSB) shares underlie Yu Rui’s option?

The option reported covers 203,464 underlying Ordinary Shares. This figure represents the total number of shares tied to the option grant, vesting over several years, rather than currently owned common shares acquired through open-market transactions.

What are the vesting terms of Yu Rui’s LakeShore Biopharma (LSB) option?

The option vests 25% of the underlying shares on December 31, 2024. The remaining 75% vests in three equal annual installments on each anniversary of the December 13, 2024 grant date, contingent on Yu Rui’s continued service to the company.

Does Yu Rui’s LakeShore Biopharma (LSB) Form 3 show any share purchases or sales?

The Form 3 does not show any purchases or sales of shares. It reports a holding entry for a share option over 203,464 underlying Ordinary Shares, detailing exercise price, expiration date, and vesting schedule instead of market trading activity.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Yu Rui

(Last) (First) (Middle)

C/O BUILDING NO. 2

38 YONGDA ROAD, DAXING DISTRICT

(Street)

BEIJING DAXING DISTRICT 102629

(City) (State) (Zip)

CHINA

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
LakeShore Biopharma Co., Ltd. [ LSB ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Share Option (Right to Buy)	(1)	12/13/2034	Ordinary Shares	203,464	$1.225	D

Explanation of Responses:

1. The option vests as to 25% of the underlying shares on December 31, 2024, and the remaining 75% vests in three equal annual installments on each anniversary of the grant date (December 13, 2024) thereafter, subject to the Reporting Person's continued service to the Issuer.

	/s/ Rui Yu	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)